top of page
Hope4ATRT Logo

Open Clinical Trials

TAZNI: A Phase I/II Combination Trial of Tazemetostat with Nivolumab and Ipilimumab for Children with INI1-Negative or SMARCA4-Deficient Tumors

Purpose of this clinical trial:

This research study involves a combination of three drugs given together as a possible treatment for malignant rhabdoid tumor, atypical teratoid rhabdoid tumor, epithelioid sarcoma, chordoma or other tumors that are deficient in one of two possible proteins, either INI-1 (SMARCB1) or SMARCA4.




Nivolumab-Ipiliumab: Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers

Purpose of this clinical trial:

The main purpose of this study is to determine the safety and effectiveness of nivolumab and ipilimumab for patients with relapsed or refractory INI1- negative tumors.  Patients with multiple types of solid tumors and brain tumors will be included as part of this study.  Patients will only be eligible for this study if their tumor has shown a mutation/deletion of a gene that is known to suppress tumor growth called INI1.

PNOC025: Magrolimab in Children and Adults with Recurrent or Progressive Malignant Brain Tumors

Purpose of this clinical trial:

The goal of this study is to test the safety and efficacy of magrolimab in children and adults with recurrent or progressive malignant brain tumors. Magrolimab is a novel antibody anticancer therapeutic agent targeting a certain protein called CD47. Binding of magrolimab to CD47 on target malignant cells blocks the "don't eat me" signal by cancer cells and enhances tumor cell phagocytosis.

BrainChild-04: Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy for Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors

Purpose of this clinical trial:

The BrainChild-04 study is investigating Seattle Children’s Therapeutics’ first CAR T-cell product that targets four antigens simultaneously: B7-H3, EGFR806, HER2 and IL13-zetakine.  This is the first known CAR T-cell product in the world to target four antigens at the same time by delivering CAR T cells directly to the brain.

MEMMAT: Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma and ATRT

Purpose of this clinical trial:

The goal of this study is to provide additional therapy options for children with recurrent or progressive medulloblastoma, ependymoma and ATRT, for whom no known curative therapy exists, by prolonging survival while maintaining good quality of life. The primary objective of the MEMMAT trial is to evaluate the activity of this multidrug antiangiogenic approach in previously treated children and young adults

Methotrexate and Etoposide Infusions Into the Fourth Ventricle in Children With Recurrent Posterior Fossa Brain Tumors

Purpose of this clinical trial:

The goal of this clinical research study is to establish the safety of simultaneous infusions of methotrexate and etoposide into the fourth ventricle of the brain or resection cavity in patients with recurrent malignant posterior fossa brain tumors. Patients' disease must have originated in the posterior fossa of the brain.

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

Purpose of this clinical trial:

This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-tumor immune response, will also be tested.

Auto Transplant for High Risk or Relapsed Solid or CNS Tumors

Purpose of this clinical trial:

This is a standard of care treatment guideline for high risk or relapsed solid tumors or CNS tumors consisting of a busulfan, melphalan, thiotepa conditioning (for solid tumors) or carboplatin and thiotepa conditioning (for CNS tumors) followed by an autologous peripheral blood stem cell transplant.

Tazemetostat: A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

Please note, this study is closed and is no longer accepting patients.


Purpose of this clinical trial:

The main purpose of this study is to establish the safety and best possible dose of tazemetostat for patients with relapsed or refractory INI1- negative tumors or synovial sarcoma.

9-ING-41 in Pediatric Patients With Refractory Malignancies

Purpose of this clinical trial:

9-ING-41 has anti-cancer clinical activity with no significant toxicity in adult patients. This Phase 1 study will study its efficacy in pediatric patients with advanced malignancies.

CLOVER-2: Dose Escalation Study of CLR 131 in Children and Adolescents With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma

Purpose of this clinical trial:

The study evaluates CLR 131 in children, adolescents, and young adults with relapsed or refractory malignant solid tumors and lymphoma and recurrent or refractory malignant brain tumors for which there are no standard treatment options with curative potential.

PBTC-051: Phase I Study of APX005M in Pediatric CNS Tumors

Please note, this study is closed and is no longer accepting patients.


Purpose of this clinical trial:

The main purpose of this study is to determine the best dose and side effects of a new drug called APX005M in treating children and young adult patients with brain cancer that is growing, spreading or getting worse.

BrainChild-01: HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors

Purpose of this clinical trial:

The main purpose of this study is to determine the side effects and best dose of HER2-specific chimeric antigen receptor (CAR) T cell immunotherapy in treating patients with brain tumors that have come back or does not respond to treatment (recurrent or refractory disease).

BrainChild-02: EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors

Purpose of this clinical trial:

The main purpose of this study is to determine if T-cell therapy is safe to give to children and young adults with recurrent (disease has returned) or refractory EGFR positive central nervous system (CNS) tumors, including ATRT, and what dose of this therapy is best.

BrainChild-03: Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors

Purpose of this clinical trial:

The main purpose of this study is to determine the safety and feasibility of B7H3-specific chimeric antigen receptor (CAR) T cell immunotherapy in treating patients with brain tumors that have come back or does not respond to treatment (recurrent or refractory disease).

MV-NIS: Modified Measles Virus for Children and Young Adults with Recurrent ATRT

Please note, this study has closed to accrual and is no longer accepting patients.


Purpose of this clinical trial:

The main purpose of MV-NIS is to study the effects of the safety and appropriate dose level of the modified measles virus (MV-NIS) in children and young adults with recurrent (disease has returned) medulloblastoma or ATRT

PBTC-050: Phase I Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors

Please note, this study is closed and is no longer accepting patients.


Purpose of this clinical trial:

The main purpose of this study is to determine the best dose and side effects of a combination of drugs and to see how well the work in treating children and young adults with brain cancer that has come back or did not respond to treatment. These drugs may stop the growth of tumor cells by inhibiting the enzymes needed for the cells to grow. Giving ribociclib and everolimus together may work better in treating these aggressive types of brain tumors.

PVSRIPO: Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children

Please note, this study is closed and is no longer accepting patients.


Purpose of this clinical trial:

The main purpose of PVSRIPO is to study the safety and appropriate dose level of the oncolytic poliovirus (PV) immunotherapy with PVSRIPO) in children and young adults with recurrent (disease has returned) grade IV ATRT.

bottom of page